Logo

Proteomic Biomarker Shop CS-Keys Closes Seed Round of VC Financing

Jul 18, 2006
NEW YORK (GenomeWeb News) - Proteomics company CS-Keys said yesterday that it has received a "significant" but undisclosed seed investment from Midwest VC firm Triathlon Medical Ventures.
 
CS-Keys, based in Indianapolis, will use the investment to continue researching and developing its cancer-specific biomarkers and supporting its marketing and regulatory strategies.
 
Earlier this year, CS-Keys received a $285,000 investment from the BioCrossroads-managed Indiana Seed Fund. Triathlon is part of the Indiana Future Fund, a $73-million fund-of-funds organized through BioCrossroads and focused on early-stage Indiana life sciences investments.
 
CS-Keys was formed in February 2005 and is using proteomics techniques to create biomarkers for identifying malignant cells.

Filed under

Proteomics & Protein Research
proteomics
Breaking News
The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.